Dr. Leah Fung is the Chief Executive Officer of Biotheryx and a member of our Board of Directors. Previously, as our Chief Scientific Officer, Dr. Fung was pivotal in the design and implementation of the Company’s PRODEGY protein degradation platform, which has generated a pipeline of first-in-class protein degraders. Dr. Fung created Biotheryx’s molecular glue screening library for novel neosubstrate discovery and directed research that resulted in more than 25 issued U.S. patents covering an extensive range of small molecule protein degraders. Prior, Dr. Fung served as Vice President of Medicinal Chemistry at NovoMedix, Associate Director of Medicinal Chemistry at Structural Genomix (acquired by Eli Lilly), and Assistant Director of Medicinal Chemistry at Structural Bioinformatics. Dr. Fung also held leadership positions in research at Signal Pharmaceuticals and Celgene. Additionally, she was among leading scientists who pioneered combinatorial chemistry technologies and has authored over 20 peer-reviewed publications. She is also co-inventor on more than 40 issued U.S. patents and hundreds of international patents. Dr. Fung received her Ph.D. in chemistry from the University of California, Irvine.

• 

  Chief Executive Officer (CEO) in Biotheryx

  Degrading proteins. Saving lives.